Longeveron to Present at Longevity Leaders World Congress; Latinos and Alzheimer’s Symposium; International Frailty and Sarcopenia Research Conference

Rhea-AI Summary

Longeveron Inc. (NASDAQ: LGVN) announces participation in key events showcasing its commitment to developing cell therapeutics for aging-related diseases. Key presentations include: April 20 - Kevin N. Ramdas discusses Lomecel-B clinical trial results at ICFSR, Boston. April 21 - Anthony Oliva presents on cognitive frailty. April 25 - Ramdas presents at the Latinos & Alzheimer’s Symposium. April 26 - Joshua Hare presents on aging and frailty at Longevity Leaders World Congress, London. The Company aims to advance its therapies into Phase 3 trials for conditions like Alzheimer's and Aging Frailty.

April events to highlight Longeveron’s commitment to developing cell therapeutics for chronic aging related diseases.

MIAMI, April 14, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today its Chief Science Officer, Co-Founder, and Chairman, Joshua Hare, M.D., F.A.C.C., F.A.H.A. will be presenting at the Longevity Leaders World Congress in April. Also this month, Longeveron Director of Medical Affairs Kevin N. Ramdas, M.D. M.P.H. will present at the upcoming 12th Annual International Conference on Frailty and Sarcopenia Research (ICFSR) as well as the 3rd Annual Latinos & Alzheimer’s Symposium hosted by the Alzheimer’s Association, where Longeveron’s Senior Scientist, Anthony Oliva, PhD will also moderate and present two oral communications.

Details of Longeveron’s participation at these events are as follows:

• 12^th Annual International Conference on Frailty and Sarcopenia Research (ICFSR)
  Title: Biomarker Results from a Phase 2b Clinical Trial Assessing Lomecel-B Infusion in Older Adults with Frailty
  Format: Live oral presentation by Kevin N. Ramdas, M.D., M.P.H., Director of Medical Affairs
  Date: April 20, 2022
  Time: 4:20 p.m. ET
  Location: Boston, Massachusetts

• 12^th Annual International Conference on Frailty and Sarcopenia Research (ICFSR)
  Title: Lomecel-B as a Geroscience Therapeutic Candidate for Cognitive Frailty
  Format: Moderating and presentation by Anthony A. Oliva, PhD, Senior Scientist
  Date: April 21, 2022
  Time: 12:00 p.m. ET
  Location: Boston, Massachusetts

• 3^rd Latinos & Alzheimer’s Symposium
  Title: Diversity, equity and inclusion in a phase 1 clinical trial assessing Lomecel-B in patients with Alzheimer’s disease
  Format: Poster session presented by Kevin N. Ramdas, M.D., M.P.H., Director of Medical Affairs
  Poster Number: 68512
  Date: April 25, 2022
  Time: 12:45 ET
  Location: Bonita Springs, Florida

• Longevity Leaders World Congress
  Title: Advancing aging frailty through the clinic with ageing clinical endpoints
  Format: Live oral presentation by Joshua Hare, M.D., F.A.C.C., F.A.H.A., Co-Founder, Chief Science Officer, and Chairman
  Date: April 26, 2022
  Time: 1:40 p.m. GMT (9:40 a.m. ET)
  Location: London, United Kingdom

• Longevity Leaders World Congress
  Title: Translating and commercializing regenerative medicine and ageing science into therapeutics and consumer products
  Format: Live panel with participation from Joshua Hare, M.D., F.A.C.C., F.A.H.A., Co-Founder, Chief Science Officer, and Chairman
  Date: April 26, 2022
  Time: 3:45 p.m. GMT (10:45 p.m. ET)
  Location: London, United Kingdom

About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company’s lead investigational product is the LOMECEL-B™ cell-based therapy product (“Lomecel-B”), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young, healthy adult donors. Longeveron believes that by using the same cells that promote tissue repair, organ maintenance, and immune system function, it can develop safe and effective therapies for some of the most difficult disorders associated with the aging process and other medical disorders. Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). The Company’s mission is to advance Lomecel-B and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization, and broad use by the healthcare community. Additional information about the Company is available at www.longeveron.com.

Contact:
Brendan Payne
Stern Investor Relations
Tel: (212) 362-1200
Email: Brendan.payne@sternir.com

Source: Longeveron

FAQ

What is Longeveron's involvement in the April 2022 events?

Longeveron will present at several events in April 2022, including the ICFSR and Longevity Leaders World Congress, focusing on Lomecel-B and its applications.

When will Kevin N. Ramdas present at the ICFSR?

Kevin N. Ramdas will present on April 20, 2022, at 4:20 p.m. ET during the 12th Annual ICFSR in Boston.

What topics will Longeveron cover at the Longevity Leaders World Congress?

At the Longevity Leaders World Congress on April 26, 2022, Joshua Hare will discuss aging frailty and regenerative medicine.

What is Lomecel-B used for?

Lomecel-B is a cell-based therapy developed by Longeveron for aging-related conditions, including Alzheimer's and frailty.

What are the clinical trials Longeveron is sponsoring?

Longeveron is sponsoring Phase 1 and 2 trials for Aging Frailty, Alzheimer’s disease, and other serious conditions.